PTHS underwent a massive business transformation with total assets increasing 9,424% to $130.4M while net losses expanded dramatically from -$8.0M to -$43.3M.
The company appears to have completed a major acquisition or merger that fundamentally changed its scale and operations, evidenced by the name change from Channel Therapeutics Corporation to Pelthos Therapeutics Inc. The dramatic asset growth suggests significant new capabilities or expanded operations, but the proportionally larger increase in losses and expenses indicates substantial integration challenges or increased operational complexity that investors need to monitor closely.
PTHS experienced extraordinary growth across all balance sheet items with assets growing 94x and stockholders' equity swinging from negative $2.7M to positive $38.9M, indicating a major capital infusion or transformative transaction. However, operational performance deteriorated significantly with SG&A expenses increasing 564% and net losses expanding 444% to -$43.3M, while operating cash flow burned 290% more at -$22.6M. The financial picture suggests a company that has dramatically expanded through acquisition or merger but is struggling with substantially higher operating costs and cash burn relative to its previous scale.
Asset base grew 9424% — expansion through organic growth, acquisitions, or capital deployment.
Current assets grew 3801% — improving short-term liquidity or inventory/receivables build.
Cash position surged 3403.5% — strong cash generation or capital raise providing significant financial cushion.
Liabilities grew 2141.3% — significant increase in debt or obligations, assess impact on financial flexibility.
Equity base grew 1532.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.
SG&A up 564.2% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Current liabilities surged 536.6% — significant near-term obligations; verify ability to meet short-term debt.
Net income declined 444.5% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Operating cash flow fell 290% — earnings quality concerns; investigate working capital changes and non-cash items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →